Grove Biopharma, a Chicago, IL-based biotechnology company, raised $30M in Series A funding.
The round was led by DCVC Bio with participation from Eli Lilly and Company, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Investments, and Portal Innovations.
The company intends to use the funds to further advance its platform and drive its lead oncology programs towards the clinic.
Led by CEO Geoffrey Duyk, Grove Biopharma is a private biotechnology company developing its proprietary Bionic Biologics platform to provide novel therapies targeting intracellular protein-protein interaction. It represent a new therapeutic modality that integrates principles of biologic and synthetic design. The platform enables the targeting of well-validated yet previously intractable disease drivers, generating new possibilities for therapeutic intervention.
A spinout from Northwestern University, Grove provides a new approach to targeting protein-protein interactions (PPI), distinguished by the following key characteristics:
- Bionic: hybrid synthetic biomolecules with enhanced functionality beyond what is possible in nature.
- Cell permeable: multivalent, chameleonic architecture enables membrane permeability for reaching intracellular targets.
- Customizable: plug-and-play design, modular construction and tunable properties to rapidly develop and implement molecules, either monofunctional or bifunctional, against any target.
FinSMEs
24/04/2025